DTIL Precision BioSciences, Inc.
$6.79▲ +5.93%
Healthcare
Other
Volume 164.2K
Avg Volume (10D) 246.3K
Key Metrics & Fundamentals
Market Cap
$187.41M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.53 - 9.62
% vs 50 MA
-2.60%
% vs 200 MA
4.63%
RSI-14
54.5
MACD Histogram
+0.0900
Beta (1Y vs SPY)
0.98
Free Cash Flow
-$13.44M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$17.62M
COGS
–
Operating Exp
$19.16M
Operating Income
-$19.16M
EBIT
-$19.16M
Pretax Income
-$32.65M
Net Income
-$32.65M
EPS (Diluted)
-1.26
Price & Volume History
Loading chart…
Recent News
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Business Wire · Oct 8, 2026 7:01 AM ET
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Investor's Business Daily · Sep 17, 2026 4:09 PM ET
Precision BioSciences Doses First Patient in Trial of Potential Duchenne Muscular Dystrophy Treatment
MT Newswires · Aug 24, 2026 6:46 AM ET
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Business Wire · Aug 24, 2026 6:01 AM ET
Precision BioSciences: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 7:24 AM ET
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 6, 2026 7:01 AM ET
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Business Wire · Jul 31, 2026 7:01 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See DTIL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.